MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$44,417K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of shor...
Stock-based compensation expense
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Purchase of short-term and long-...
Repayment of loan payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net loss
-81,566
-141,230
Stock-based compensation expense
9,261
17,839
Non-cash lease expense
69
134
Net amortization of premiums and discounts on marketable securities
2,429
5,323
Amortization of debt issuance costs and discount
179
364
Unrealized foreign exchange gain and loss
-
-26
Loss on extinguishment of loan payable
-1,557
-
Fair value change in warrant liability
-400
206
Prepaid expenses and other assets
-5,489
-5,104
Accounts payable
7,176
4,203
Accrued expenses and other current liabilities
-6,408
2,908
Operating lease liability
-73
-141
Net cash used in operating activities
-67,171
-115,910
Purchase of short-term and long-term marketable securities
73,496
658,977
Proceeds from maturities of short-term marketable securities
130,277
256,134
Net cash (used in) investing activities
56,781
-402,843
Proceeds from the exercise of stock options
3,371
10,371
Proceeds from the issuance of common stock pursuant to employee stock purchase plan purchases
0
458
Proceeds from the issuance of common stock and pre-funded warrants in a follow-on public offering
0
378,350
Proceeds from the issuance of common stock pursuant to the atm offering
0
10,361
Repayment of loan payable
37,398
-
Payment of debt and equity issuance costs
0
576
Net cash provided by financing activities
-34,027
398,964
Net (decrease) increase in cash and cash equivalents
-44,417
-119,789
Cash and cash equivalents at beginning of period
340,238
-
Cash and cash equivalents at end of period
176,032
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of short-term...
$130,277K
Net cash (used in)
investing activities
$56,781K
Canceled cashflow
$73,496K
Net (decrease)
increase in cash and cash...
-$44,417K
Canceled cashflow
$56,781K
Stock-based compensation
expense
$9,261K
Accounts payable
$7,176K
Prepaid expenses and
other assets
-$5,489K
Loss on
extinguishment of loan payable
-$1,557K
Amortization of debt issuance
costs and discount
$179K
Non-cash lease expense
$69K
Proceeds from the
exercise of stock options
$3,371K
Purchase of short-term
and long-term...
$73,496K
Net cash used in
operating activities
-$67,171K
Canceled cashflow
$23,731K
Net cash provided by
financing activities
-$34,027K
Canceled cashflow
$3,371K
Net loss
-$81,566K
Accrued expenses and
other current...
-$6,408K
Net amortization of
premiums and discounts on...
$2,429K
Fair value change in
warrant liability
-$400K
Operating lease liability
-$73K
Repayment of loan payable
$37,398K
Buy us a coffee
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (AKRO)